Workflow
君实生物(688180) - 2021 Q1 - 季度财报
2021-04-29 16:00

Financial Performance - Net profit attributable to shareholders reached CNY 377,321,280.11, a significant turnaround from a loss of CNY 229,358,722.62 in the same period last year[5] - Operating revenue surged by 838.81% to CNY 1,615,115,584.67, compared to CNY 172,039,232.78 in the previous year[5] - Basic and diluted earnings per share were CNY 0.43, compared to a loss of CNY -0.29 in the same period last year[5] - Net profit for Q1 2021 was ¥377,320,986.58, compared to a net loss of ¥229,359,114.54 in Q1 2020, indicating a turnaround in profitability[20] - The total comprehensive income for Q1 2021 was approximately ¥648 million, contrasting with a total comprehensive loss of ¥190 million in Q1 2020[22] Cash Flow - Net cash flow from operating activities was CNY 399,613,641.51, a recovery from a negative cash flow of CNY -353,500,138.36 in the same period last year[5] - The company reported a net cash flow from operating activities of approximately ¥400 million in Q1 2021, compared to a negative cash flow of ¥354 million in Q1 2020[23] - Total cash inflow from operating activities reached ¥1,723,618,457.21, while cash outflow was ¥1,061,995,803.38, resulting in a net cash inflow of ¥661,622,653.83[25] Assets and Liabilities - Total assets increased by 6.94% to CNY 8,552,401,128.61 compared to the end of the previous year[5] - Total assets as of March 31, 2021, amounted to ¥8,552,401,128.61, up from ¥7,997,409,506.14 at the end of 2020[17] - Total liabilities as of March 31, 2021, were ¥1,490,203,703.39, up from ¥1,183,603,327.38 at the end of 2020, representing an increase of about 26%[19] Research and Development - R&D expenditure as a percentage of operating revenue decreased by 98.41 percentage points to 27.90% from 126.31% in the previous year[5] - R&D expenses rose to ¥450,649,443.76, a 107.38% increase from ¥217,301,553.90, attributed to the expansion of the R&D pipeline and collaborative projects[13] - Research and development expenses for Q1 2021 amounted to approximately ¥290 million, up from ¥183 million in Q1 2020, reflecting a year-over-year increase of about 59%[22] Shareholder Information - The total number of shareholders at the end of the reporting period was 26,672[8] - The top shareholder, HKSCC NOMINEES LIMITED, held 20.94% of the shares[8] Government Subsidies and Other Income - The company reported a government subsidy of CNY 23,159,002.63 related to its normal business operations[7] - Other income surged to ¥22,477,472.48, a 5,971.57% increase from ¥370,208.48, mainly due to new government subsidies[13] - The company reported other income of ¥22,477,472.48 in Q1 2021, compared to ¥370,208.48 in Q1 2020, indicating a substantial increase[20]